These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 16963792)

  • 21. Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions.
    Ito K; Sugiyama Y
    Trends Pharmacol Sci; 2010 Aug; 31(8):351-5. PubMed ID: 20542578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of drug-drug interactions: concepts and approaches.
    Weaver RJ
    Xenobiotica; 2001; 31(8-9):499-538. PubMed ID: 11569524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
    Wilkinson GR
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs.
    Crivori P; Poggesi I
    Eur J Med Chem; 2006 Jul; 41(7):795-808. PubMed ID: 16644065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery.
    Masimirembwa CM; Thompson R; Andersson TB
    Comb Chem High Throughput Screen; 2001 May; 4(3):245-63. PubMed ID: 11375740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist.
    Cruciani G; Carosati E; De Boeck B; Ethirajulu K; Mackie C; Howe T; Vianello R
    J Med Chem; 2005 Nov; 48(22):6970-9. PubMed ID: 16250655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated cytotoxicity mechanism screening using drug metabolising enzyme modulators.
    O'Brien PJ; Siraki AG
    Curr Drug Metab; 2005 Apr; 6(2):101-9. PubMed ID: 15853762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.
    Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H
    Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro screening of drug metabolism during drug development: can we trust the predictions?
    Pelkonen O; Raunio H
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):49-59. PubMed ID: 16922652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug metabolism and drug interactions: application and clinical value of in vitro models.
    Venkatakrishnan K; von Moltke LL; Obach RS; Greenblatt DJ
    Curr Drug Metab; 2003 Oct; 4(5):423-59. PubMed ID: 14529374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro evaluation of metabolic drug-drug interactions: a descriptive and critical commentary.
    Li AP
    Curr Protoc Toxicol; 2007; Chapter 4():Unit 4.25. PubMed ID: 23045147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico site of metabolism prediction of cytochrome P450-mediated biotransformations.
    Tarcsay Á; Keseru GM
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):299-312. PubMed ID: 21291341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human hepatic cell cultures: in vitro and in vivo drug metabolism.
    Gómez-Lechón MJ; Donato T; Ponsoda X; Castell JV
    Altern Lab Anim; 2003; 31(3):257-65. PubMed ID: 15612868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions.
    Lu C; Liao M; Cohen L; Xia CQ
    Curr Drug Discov Technol; 2010 Sep; 7(3):199-222. PubMed ID: 20843292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of input parameters on the prediction of hepatic plasma clearance using the well-stirred model.
    Wan H; Bold P; Larsson LO; Ulander J; Peters S; Löfberg B; Ungell AL; Någård M; Llinàs A
    Curr Drug Metab; 2010 Sep; 11(7):583-94. PubMed ID: 20629632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of metabolism-mediated herb-drug interactions.
    Na DH; Ji HY; Park EJ; Kim MS; Liu KH; Lee HS
    Arch Pharm Res; 2011 Nov; 34(11):1829-42. PubMed ID: 22139684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery.
    Bell LC; Wang J
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1131-55. PubMed ID: 22681474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation: in vitro study design.
    McConn DJ; Zhao Z
    Curr Drug Metab; 2004 Apr; 5(2):141-6. PubMed ID: 15078191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes.
    Dmitriev AV; Lagunin AA; Karasev DА; Rudik AV; Pogodin PV; Filimonov DA; Poroikov VV
    Curr Top Med Chem; 2019; 19(5):319-336. PubMed ID: 30674264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic stability: main enzymes involved and best tools to assess it.
    Laine R
    Curr Drug Metab; 2008 Nov; 9(9):921-7. PubMed ID: 18991589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.